A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function-Reference-Cited by-同舟云学术

A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

Published:2013-01 Issue:1 Volume:19 Page:56-61
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Abidi Muneer H.,Agarwal Rishi,Tageja Nishant,Ayash Lois,Deol Abhinav,Al-Kadhimi Zaid,Abrams Judith,Cronin Simon,Ventimiglia Marie,Lum Lawrence,Ratanatharathorn Voravit,Zonder Jeffrey,Uberti Joseph

Funder

Biovitrum pharmaceuticals

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference29 articles.

1. Multiple myeloma;Raab;Lancet,2009

2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;N Engl J Med,1996

3. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe;Fermand;J Clin Oncol,2005

4. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

5. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010;Bladé;Blood,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis;Bone Marrow Transplantation;2024-04-24

2. Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study;The Egyptian Heart Journal;2024-02-01

3. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m² versus 200mg/m² preparative regimens in patients with multiple myeloma;Leukemia & Lymphoma;2023-05-18

4. Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma;European Journal of Clinical Pharmacology;2022-10-07

5. Keratinocyte growth factor in focus: A comprehensive review from structural and functional aspects to therapeutic applications of palifermin;International Journal of Biological Macromolecules;2021-11